Literature DB >> 18799105

Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients. A systematic review of the literature.

L Lévy1, B Fautrel, T Barnetche, T Schaeverbeke.   

Abstract

BACKGROUND: There is substantial evidence of excess cardiovascular morbidity and mortality in rheumatoid arthritis (RA) patients, but the related studies showed important variations in the estimation of the risk. We conducted a meta-analysis to evaluate more accurately the incidence of cardiovascular events, and the excess of cardiovascular risk in a population of RA patients.
METHODS: The authors searched for observational studies accounting for the number of myocardial infarction or stroke events, using Medline, and congress abstracts published until February 2006. The populations studied were adults and RA diagnosis was based on the American College of Rheumatology (ACR) criteria. We calculated the incidence of myocardial infarction and cerebrovascular fatal events in RA patients and estimated the cardiovascular risk increase for RA patients compared with the control group.
RESULTS: 17 publications and abstracts were identified, 15 were selected for the meta-analysis (two publications were excluded because of the lack of person-years information). The incidence of fatal myocardial infarction was 13.3 for 1000 RA patients-year (IC95%=[13-13.6]). The incidence of fatal cerebrovascular accident was 4.5 for 1000 RA patients-year (IC95%=[4.3-4.7]). Risk of myocardial ischemia in RA patients was about 1.63 compared to the general population (OR=1.63, IC95%=[1.34-2]). No excess was found for the risk of stroke event in RA patients.
CONCLUSION: RA patients were reported to present an excess risk of fatal myocardial infarction compared to the general population. The prevention of cardiovascular complications, including management of cardiovascular risk factors and control of systemic inflammation, should be taken into account by the rheumatologist.

Entities:  

Mesh:

Year:  2008        PMID: 18799105

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  39 in total

Review 1.  Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis.

Authors:  Silvio Romano; Elisa Salustri; Piero Ruscitti; Francesco Carubbi; Maria Penco; Roberto Giacomelli
Journal:  Curr Rheumatol Rep       Date:  2018-11-05       Impact factor: 4.592

2.  Connecting Rheumatology Patients to Primary Care for High Blood Pressure: Specialty Clinic Protocol Improves Follow-up and Population Blood Pressures.

Authors:  Christie M Bartels; Edmond Ramly; Heather M Johnson; Diane R Lauver; Daniel J Panyard; Zhanhai Li; Emmanuel Sampene; Kristin Lewicki; Patrick E McBride
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04       Impact factor: 4.794

3.  Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease.

Authors:  Keiichi Sumida; Miklos Z Molnar; Praveen K Potukuchi; Fatima Hassan; Fridtjof Thomas; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Kidney Int       Date:  2018-03-02       Impact factor: 10.612

Review 4.  Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.

Authors:  Debbie T Lim; Amy C Cannella; Kaleb D Michaud; Ted R Mikuls
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

5.  Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis.

Authors:  Pierpaolo Di Micco; Paola Ferrazzi; Luca Librè; Loredana Mendolicchio; Ilaria Quaglia; Monica De Marco; Anna Colombo; Monica Bacci; Lidia Luciana Rota; Corrado Lodigiani
Journal:  Int J Gen Med       Date:  2009-07-30

Review 6.  B Lymphocytes in Rheumatoid Arthritis and the Effects of Anti-TNF-α Agents on B Lymphocytes: A Review of the Literature.

Authors:  Ozlem Pala; Alain Diaz; Bonnie B Blomberg; Daniela Frasca
Journal:  Clin Ther       Date:  2018-05-23       Impact factor: 3.393

7.  Risk factors for coronary heart disease in connective tissue diseases.

Authors:  Awal Al Husain; Ian N Bruce
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

8.  Subendocardial viability ratio in patients with rheumatoid arthritis: comparison with healthy controls and identification of prognostic factors.

Authors:  Panagiota Anyfanti; Areti Triantafyllou; Eugenia Gkaliagkousi; Georgios Triantafyllou; Nikolaos Koletsos; Sophia Chatzimichailidou; Panagiotis Panagopoulos; Ioannis Botis; Spyros Aslanidis; Stella Douma
Journal:  Clin Rheumatol       Date:  2017-04-28       Impact factor: 2.980

9.  Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.

Authors:  Laura Bazzichi; Lorenzo Ghiadoni; Alessandra Rossi; Melania Bernardini; Mario Lanza; Francesca De Feo; Camillo Giacomelli; Ilaria Mencaroni; Katia Raimo; Marco Rossi; Anna Maria Mazzone; Stefano Taddei; Stefano Bombardieri
Journal:  Mol Med       Date:  2009-06-18       Impact factor: 6.354

Review 10.  Cardiovascular comorbidity in rheumatic diseases.

Authors:  Michael T Nurmohamed; Maaike Heslinga; George D Kitas
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.